| case report | Q2782326 |
| scholarly article | Q13442814 |
| P50 | author | Julie-An Talano | Q73392651 |
| Larisa Broglie | Q89777235 | ||
| P2093 | author name string | Sridhar Rao | |
| David Margolis | |||
| Rachel Phelan | |||
| Lauren Pommert | |||
| Monica Thakar | |||
| P2860 | cites work | Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis | Q42576897 |
| Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis | Q43867826 | ||
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 | ||
| Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. | Q53916622 | ||
| Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. | Q54533845 | ||
| Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids | Q82950882 | ||
| Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis | Q84751886 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib | Q33402522 | ||
| Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis | Q33429617 | ||
| Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 | ||
| Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. | Q34433867 | ||
| HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. | Q34561113 | ||
| Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol | Q35525318 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Biology and significance of the JAK/STAT signalling pathways | Q37146441 | ||
| Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience | Q38992336 | ||
| Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis | Q40360876 | ||
| Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis | Q40490433 | ||
| Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. | Q42260141 | ||
| P433 | issue | 19 | |
| P921 | main subject | hemophagocytic lymphohistiocytosis | Q1642170 |
| ruxolitinib | Q7383611 | ||
| P304 | page(s) | 1533-1536 | |
| P577 | publication date | 2017-08-17 | |
| P1476 | title | Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis | |
| P478 | volume | 1 |
| Q90857636 | A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation |
| Q95840998 | Cell Versus Cytokine - Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity |
| Q91973589 | Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complicat |
| Q91763430 | Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis |
| Q90249953 | Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis |
| Q99561362 | Primary immune regulatory disorders: a growing universe of immune dysregulation |
| Q90746855 | Recent advances in primary immunodeficiency: from molecular diagnosis to treatment |
| Q91844259 | Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib |
| Q90181685 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial |
| Q92525829 | Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis |
| Q90745265 | The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature |
| Q95637970 | The immunology of COVID-19: is immune modulation an option for treatment? |
| Q89540069 | Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid |
| Q95264258 | Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes |
Search more.